MedTrace Logo

Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

NCT05753189 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 362

Last updated 2026-05-13

Study results available
· View outcomes & findings →

Summary

Safety Study of the Long-Term Safety of LNZ100 \& LNZ101 in Presbyopic Subjects

Conditions

  • Presbyopia
  • Near Vision
  • Refractive Error
  • Eye Diseases

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

Aceclidine + Brimonidine combination ophthalmic solution

DRUG

Aceclidine ophthalmic solution

Aceclidine ophthalmic solution

DRUG

Vehicle

Vehicle

Sponsors & Collaborators

  • LENZ Therapeutics, Inc

    lead OTHER

Principal Investigators

  • Kris Gambelin, BS · LENZ Therapeutics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-21
Primary Completion
2024-02-09
Completion
2024-02-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05753189 on ClinicalTrials.gov